1GAAP operating loss narrowed 19.8% year-over-year to $59.3 million in FY2025, compared to a $73.9 million loss in FY2024.
2GAAP net loss narrowed 14.6% year-over-year to $59.6 million in FY2025, down from a $69.8 million loss in the prior fiscal year.
3Diluted GAAP EPS improved 29.9% year-over-year to -$1.01 in FY2025, compared to a diluted EPS of -$1.44 for FY2024.
4The company does not expect to generate meaningful product revenue for the foreseeable future, as it incurs significant costs for clinical development of its product candidates.
5Management expects near-term reductions in research and development expenses as Phase 2 trials for certain indications are completed, paired with cost containment and capital preservation initiatives.
6BioAtla faces potential going concern risk if it cannot secure sufficient capital when needed, and may pursue equity or convertible debt raises even if it deems current funds adequate for operations.